Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings

2Citations
Citations of this article
23Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Background Vaginal rings formulated to deliver two drugs simultaneously have potential as user-controlled, long-acting methods for dual prevention of HIV and pregnancy. Methods Two phase 1 randomized trials (MTN-030/IPM 041 and MTN-044/IPM 053/CCN019) respectively enrolled 24 and 25 healthy, HIV-negative participants to evaluate safety, pharmacokinetics, and vaginal bleeding associated with use of a vaginal ring containing 200mg dapivirine (DPV) and 320mg levonorgestrel (LNG) designed for 90-day use. MTN-030/IPM 041 compared the DPV/LNG ring to a DPV-only ring (200mg) over 14 days of use. MTN-044/IPM 053/CCN019 compared continuous or cyclic use of the DPV/LNG ring over 90 days of use. Safety was assessed by recording adverse events (AEs). DPV and LNG concentrations were quantified in plasma, cervicovaginal fluid, and cervical tissue. Vaginal bleeding was self-reported. Results There were no differences in the proportion of participants with grade 2 genitourinary AEs or grade 3 AEs with DPV/LNG ring vs. DPV ring use (p = .22), or with DPV/LNG ring continuous vs. cyclic use (p = .67). Higher plasma DPV concentrations were observed in users of DPV/LNG compared to DPV-only rings (Cmax p = 0.049; AUC p = 0.091). Plasma DPV and LNG concentrations were comparable with continuous and cyclic use (Cmax p = 0.74; AUC p = 0.25). With cyclic use, median nadir plasma DPV concentration was approximately 300 pg/mL two days after removal and median t1/2 for cervicovaginal fluid DPV concentration was 5.76 hours (n = 3). Overall bleeding experiences did not differ between continuous and cyclic users (p = 0.12). Conclusions The extended duration DPV/ LNG rings were well tolerated and the observed DPV concentrations in plasma and cervicovaginal fluid when used continuously exceeded concentrations observed in previous DPV ring efficacy studies. LNG concentrations in plasma were comparable with other efficacious LNG-based contraceptives. Genital DPV concentrations had a short half-life and were thus not well sustained following ring removal.

References Powered by Scopus

Unintended pregnancy and abortion by income, region, and the legal status of abortion: estimates from a comprehensive model for 1990–2019

677Citations
N/AReaders
Get full text

Use of a vaginal ring containing dapivirine for HIV-1 prevention in women

656Citations
N/AReaders
Get full text

Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women

394Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Preventing HIV in women in Africa

0Citations
N/AReaders
Get full text

Acceptability of a dapivirine levonorgestrel vaginal ring in two Phase 1 trials (MTN-030/ IPM 041 and MTN-044/IPM 053/CCN019): Implications for multipurpose prevention technology development

0Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Achilles, S. L., Kelly, C. W., Hoesley, C. J., Blithe, D. L., Brown, J., Richardson, B. A., … Chen, B. A. (2024). Phase 1 randomized trials to assess safety, pharmacokinetics, and vaginal bleeding associated with use of extended duration dapivirine and levonorgestrel vaginal rings. PLoS ONE, 19(6 June). https://doi.org/10.1371/journal.pone.0304552

Readers' Seniority

Tooltip

Professor / Associate Prof. 1

50%

PhD / Post grad / Masters / Doc 1

50%

Readers' Discipline

Tooltip

Nursing and Health Professions 2

67%

Pharmacology, Toxicology and Pharmaceut... 1

33%

Save time finding and organizing research with Mendeley

Sign up for free